Post-earnings recap
Reported
Wed, Aug 12, 2026
EPS actual
$0.52
EPS est.
$0.46
EPS surprise
+13.54%
1-day move
+0.11%
Bio-Techne Corporation reported earnings that matched expectations on EPS, leading to a slight increase in stock price by 0.11%. However, there was no revenue reported, which leaves some uncertainty about overall performance. Investors may be encouraged by the EPS beat, but the lack of revenue information could raise questions about future growth.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.52 | $0.52 | +13.54% |
| Revenue | N/A | $315M | N/A |
No transcript is on record, and the analysis is based on numerical results only.
Bio-Techne Corporation operates in the health care sector, focusing on life sciences tools and services. The company provides critical products for research and clinical diagnostics, making it significant in advancing scientific and medical discoveries.
Last quarter
In Q3-2026, Bio-Techne reported an EPS of $0.53, exceeding expectations by 11.11%. However, the stock fell 16.36% the following day, indicating market concerns despite the earnings beat.
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+21.10%
Avg 1-day reaction
-0.91%
Analysts expect Bio-Techne to report solid earnings, with a consensus EPS of $0.52 and revenue of $315 million. The market is keenly watching for any signs of growth or challenges in demand.
Bull case
If Bio-Techne exceeds expectations, it could signal strong demand for its products, leading to increased investor confidence and a potential rise in stock price.
Bear case
Conversely, if the company fails to meet earnings expectations or provides weak guidance, it could lead to a significant drop in stock price, reflecting investor disappointment.
Key metrics to watch
EPS
0.52Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating income.
Revenue
315MRevenue figures will indicate the overall demand for Bio-Techne's products and services, reflecting market conditions and company performance.
The print will turn on these.
Q1
Will Bio-Techne's revenue exceed the consensus estimate of $315 million?
Revenue performance will be crucial in assessing the company's market demand and growth trajectory.
Q2
What guidance will management provide regarding future earnings and market conditions?
Management's outlook will heavily influence investor sentiment and expectations for the upcoming quarters.
—
Est. EPS
$0.20
Est. Rev
$609M
Impl. Move
±12.7%
Why consensus could be wrong
The consensus may underestimate Bio-Techne's ability to leverage new product innovations, which could drive unexpected revenue growth.
Supporting evidence
The company has consistently beaten EPS estimates, indicating stronger operational performance than anticipated.
The options market is pricing a significant move, suggesting that investors are expecting more volatility than historical performance would suggest.
Key risk
If revenue comes in below $312 million, it could undermine the bullish narrative and lead to a reassessment of growth prospects.
Pre-commit to what would confirm each case.
This quarter's performance is critical as it will indicate whether Bio-Techne can maintain its growth trajectory amid market challenges.
Bull confirmed if
Revenue growth exceeding $315 million with strong demand signals could confirm a bullish outlook.
Bear confirmed if
Revenue falling short of $312 million could validate concerns about declining demand.
What the market is pricing for the move.
Implied Move
±30.67%
Historical Avg
±5.8%
The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.
Options are pricing ±30.7% while TECH has averaged ±5.8% over the last 8 prints — setup is pricing rich.
ATM IV
0.6%
30d HV
80.0%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Bio-Techne beats earnings expectations, history suggests a potential average move of +2.89%, confirming strong demand and growth.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors await further clarity from management.
Miss
A miss could lead to a decline, with historical data suggesting an average drop of -2.11%, reflecting investor disappointment.
The lines on the call that would change the story.